Alsevalimab is under study as an experimental medicinal agent targeting human B7-H4. The immunotherapy exhibits initial efficacy in various malignant forms by inhibiting B7-H4 protein's function in tumor progression and patient escape. Future patient investigations aim to assess Alsevalimab's well-being and clinical benefit for patients with variou